Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

PEAK Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

Status: Completed

Protocol number: ML17756

Sponsor: Hoffmann-La Roche

Company division: Pharmaceutical

Official Scientific Title: A randomized, open-label study to compare the effect of PEGASYS plus ribavirin and PEG-Intron plus ribavirin on viral load reduction in interferon-naïve patients with chronic hepatitis C viral infection

Brief summary: This study will examine the viral kinetics and pharmacokinetics of PEGASYS plus ribavirin and PEG-Intron plus ribavirin in interferon-naive patients with CHC. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals. Target sample size is 344.

Study phase: IV

Study type: Interventional; Treatment; Randomized; Open Label; Active; Parallel; Pharmacodynamics study

Condition: Hepatitis C, Chronic

Intervention type: Drug

Intervention name: peginterferon alfa-2a (40KD) [PEGASYS]

Primary outcome: 1. Viral load reduction from baseline. Time frame: Week 12

Key secondary outcomes: 1. Viral load reduction Time frame: Weeks 4 and 8 2. Viral AUC and AAUCMB. Time frame: Weekly 3. AEs, laboratory parameters. Time frame: Throughout study

Inclusion criteria:

  • adult patients at least 18 years of age
  • CHC infection, genotype 1
  • use of 2 forms of contraception during study in both men and women

Exclusion criteria:

  • previous systemic therapy with anti-viral, anti-neoplastic, or immunomodulatory agents
  • medical condition associated with chronic liver disease (eg, hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposure)
  • decompensated liver disease
  • women who are pregnant or breastfeeding

Gender: Males or Females

Age limits: Min: 18 Years Max: N/A (No limit)

Accepts healthy volunteers: No

Trial registration date: 08/26/2005

Date last updated: 12/19/2008


Link to trial result

This trial was conducted at the following locations:

United States

  • Birmingham, AL
  • Little Rock, AR
  • Sacramento, CA
  • San Diego , CA
  • San Francisco, CA
  • San Mateo, CA
  • San Rafael, CA
  • Farmington, CT
  • Hartford, CT
  • Miami, FL
  • Sarasota , FL
  • Wellington, FL
  • Chicago, IL
  • Kansas City, KS
  • New Orleans, LA
  • Baltimore, MD
  • Boston, MA
  • Burlington, MA
  • Detroit, MI
  • Kansas City, MO
  • St Louis, MO
  • Omaha, NE
  • Las Vegas, NV
  • East Orange, NJ
  • Egg Harbour Township, NJ
  • Vineland, NJ
  • Bronx, NY
  • New York, NY
  • Poughkeepsie, NY
  • Charlotte, NC
  • Fayetteville, NC
  • Portland, OR
  • Pittsburgh, PA
  • Columbia, SC
  • Austin, TX
  • Dallas, TX
  • Salt Lake City, UT
  • Fairfax , VA
  • Norfolk , VA
  • Roanoke, VA
  • Tacoma, WA
  • Racine, WI

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply